Bio-Techne, a life sciences company, agreed to acquire a 20% stake in Wilson Wolf, a developer and manufacturer of cell culture technologies. Financial terms are not disclosed. "The explosive growth in cell and gene therapy is reminiscent of the monoclonal antibody field that Bio-Techne was founded on. CGT's lifesaving technology is now being touted as the 4th pillar of cancer treatment. The key to CGT lies in manufacturing simplicity, and we believe Wilson Wolf's G-Rex technology has the necessary attributes to bring CGT manufacturing to the simplest state while delivering the most robust cancer killing cells," Chuck Kummeth, Bio-Techne President and CEO.